Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study
Cardiovascular (CV) risk may remain despite statin treatment, and there is a need to address this risk with add-on therapy. The lipid effects of two different prescription omega-3 fatty acid therapies are described in a 55-year-old statin- and niacin-treated female with severe dyslipidemia and high...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Libertas Academica
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957603/ |